Modified Antisense Oligonucleotides for CTGF Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents are ineffective in inhibiting the synthesis of connective tissue growth factor (CTGF), a key protein involved in fibrotic diseases and scarring, and existing strategies for modulating CTGF function have limitations, such as pluripotent effects unrelated to scar formation and neglecting TGF-β independent functions.
Innovation Solution
Development of modified antisense oligonucleotides (ASOs) targeting specific sequences within the CTGF mRNA or genomic regions, which are more potent than previously described ASOs, capable of inhibiting CTGF expression and reducing scarring by hybridizing with nucleic acids encoding CTGF, thereby modulating its production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antisense oligonucleotides are used to target CTGF, then some inhibition of CTGF expression is achieved, but the inhibition potency is insufficient and therapeutic effect is limited
Solution Approach 1:
The patent modifies the chemical structure of antisense oligonucleotides by incorporating 2'-O-methoxyethyl (2'-MOE) sugar modifications and phosphorothioate backbone modifications. These parameter changes in the molecular structure significantly enhance the potency of CTGF expression inhibition, achieving up to 90-95% reduction in CTGF mRNA levels compared to conventional unmodified ASOs, thereby resolving the insufficiency of inhibition potency
Solution Approach 2:
The invention creates composite oligonucleotide structures combining multiple modification types: 2'-MOE modified nucleosides at specific positions (5' and 3' wings), phosphorothioate linkages for enhanced stability, and a central gap region with unmodified or differently modified nucleotides. This composite design synergistically improves both binding affinity to CTGF mRNA and resistance to nucleases, achieving superior therapeutic effectiveness
2Ease of manufacture
If existing therapeutic agents are used, then treatment is provided, but they are ineffective in inhibiting CTGF synthesis
Solution Approach 1:
The patent applies chemical modifications to ASO structures including 2'-MOE sugar modifications that enhance binding affinity and phosphorothioate backbone modifications that improve nuclease resistance. These parameter changes transform conventional ASOs into highly potent inhibitors of CTGF synthesis, achieving reliable inhibition where existing agents failed
Solution Approach 2:
The invention creates improved copies of conventional antisense oligonucleotides by incorporating specific modifications at defined positions. These modified copies maintain the target sequence specificity for CTGF mRNA while dramatically enhancing the inhibition of CTGF synthesis through improved hybridization stability and cellular uptake
3Adaptability or versatility
If TGF-β targeting strategies are used, then some fibrotic effects are addressed, but TGF-β independent functions of CTGF are neglected and pluripotent effects unrelated to scar formation occur
Solution Approach 1:
The patent extracts and specifically targets CTGF as a distinct therapeutic target separate from TGF-β. By designing ASOs that specifically bind to CTGF mRNA sequences, the invention isolates the anti-fibrotic effect to CTGF inhibition alone, eliminating pluripotent effects from TGF-β pathway interference while maintaining treatment versatility for fibrotic diseases
Solution Approach 2:
The modified ASOs serve as specific intermediaries that selectively inhibit CTGF expression without affecting TGF-β signaling. This intermediary approach allows precise modulation of CTGF-dependent fibrotic pathways while avoiding off-target effects on other growth factor pathways, resolving the issue of harmful pluripotent effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified ASOs effectively inhibit CTGF expression, reducing scarring and fibrotic responses, as demonstrated by significant reductions in CTGF and Col1A2 mRNA expression in skin wounds and plasma enzyme levels, indicating decreased collagen deposition and fibrotic activity.
Implementation Method 1
An antisense compound is an oligomeric compound that is capable of undergoing hybridization to a target nucleic acid (e.g. a target mRNA molecule)
Data Source
Figure 1
Figure 2
Figure 3
AI summary
This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue growth factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.